ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...
ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...
CULVER CITY, Calif., March 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...
Get Our Latest Stock Report on ImmunityBio ImmunityBio Stock Up 0.3 % NASDAQ:IBRX opened at $3.00 on Monday. The firm has a market capitalization of $2.09 billion, a P/E ratio of -3.26 and a beta ...
13d
ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of ...
Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...
SAN DIEGO — SAN DIEGO — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $59.2 million in its fourth quarter. The San Diego-based company said it had a loss of 9 cents per share. Losses, adjusted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback